Biosimilars in the management of chronic inflammatory diseases: The Dutch experience

These days, the use of biosimilars for the treatment of bio-naive patients is well established. However, the transition of patients being treated with a bio-originator to its biosimilar is still a topic of discussion. The main issue is which approach to use when initiating the non-medical transition...

Descripción completa

Detalles Bibliográficos
Autores principales: Müskens, Wieland D., Rongen-van Dartel, Sanne A. A., Adang, Eddy M. M., van Riel, Piet L. C. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280871/
https://www.ncbi.nlm.nih.gov/pubmed/32524082
http://dx.doi.org/10.31138/mjr.30.1.76

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280871/
https://www.ncbi.nlm.nih.gov/pubmed/32524082
http://dx.doi.org/10.31138/mjr.30.1.76

Ejemplares similares